Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice
Background:Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently de...
Gespeichert in:
| Veröffentlicht in: | Circulation Journal 2020/05/25, Vol.84(6), pp.1028-1033 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1033 |
|---|---|
| container_issue | 6 |
| container_start_page | 1028 |
| container_title | Circulation Journal |
| container_volume | 84 |
| creator | Deguchi, Hiroko Ikeda, Masataka Ide, Tomomi Tadokoro, Tomonori Ikeda, Soichiro Okabe, Kosuke Ishikita, Akihito Saku, Keita Matsushima, Shouji Tsutsui, Hiroyuki |
| description | Background:Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury.Methods and Results:RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.Conclusions:RXD pretreatment may be a novel strategy against I/R injury. |
| doi_str_mv | 10.1253/circj.CJ-19-1039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2384212057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2384212057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c706t-8add95bd9877a63ff4aae7d308af26c4137b1c2c3c1f449baee37910a9da42523</originalsourceid><addsrcrecordid>eNpFkMtLw0AQhxdRbH3cPUmOXqL7ymOPUqy2WATR8zLZnejGNKm7CZj_3tRWvcwMzDc_ho-QC0avGU_EjXHeVNezZcxUzKhQB2TKhMximXN6-DOnscqlmJCTECpKuaKJOiYTwTkTGadTsnxuv8D2oYMuWoH_QFsP0TPa3mCIVkNrwFsHdbQI5h3XDsbdBn3ZB9c20aKpej9ErolWzuAZOSqhDni-76fkdX73MnuIH5_uF7Pbx9hkNO3iHKxVSWFVnmWQirKUAJhZQXMoeWrk-FjBDDfCsFJKVQCiyBSjoCxInnBxSq52uRvffvYYOr12wWBdQ4NtHzQXueSM0yQbUbpDjW9D8FjqjXdr8INmVG8N6h-DerbUTOmtwfHkcp_eF2u0fwe_ykZgvgOqUdob_gHgO2dq3CfmUqfb8p_8D7yD19iIb2DGhxU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2384212057</pqid></control><display><type>article</type><title>Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Deguchi, Hiroko ; Ikeda, Masataka ; Ide, Tomomi ; Tadokoro, Tomonori ; Ikeda, Soichiro ; Okabe, Kosuke ; Ishikita, Akihito ; Saku, Keita ; Matsushima, Shouji ; Tsutsui, Hiroyuki</creator><creatorcontrib>Deguchi, Hiroko ; Ikeda, Masataka ; Ide, Tomomi ; Tadokoro, Tomonori ; Ikeda, Soichiro ; Okabe, Kosuke ; Ishikita, Akihito ; Saku, Keita ; Matsushima, Shouji ; Tsutsui, Hiroyuki</creatorcontrib><description>Background:Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury.Methods and Results:RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.Conclusions:RXD pretreatment may be a novel strategy against I/R injury.</description><identifier>ISSN: 1346-9843</identifier><identifier>ISSN: 1347-4820</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.CJ-19-1039</identifier><identifier>PMID: 32213720</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Animals ; Cell Respiration - drug effects ; Cells, Cultured ; Disease Models, Animal ; Enzyme Inhibitors - pharmacology ; Glycine - analogs & derivatives ; Glycine - pharmacology ; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism ; Hypoxia-inducible factor-1α (Hif-1α) ; Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors ; Hypoxia-Inducible Factor-Proline Dioxygenases - metabolism ; Ischemia/reperfusion injury ; Isoquinolines - pharmacology ; Male ; Mice, Inbred C57BL ; Myocardial Infarction - metabolism ; Myocardial Infarction - pathology ; Myocardial Infarction - prevention & control ; Myocardial Reperfusion Injury - metabolism ; Myocardial Reperfusion Injury - pathology ; Myocardial Reperfusion Injury - prevention & control ; Myocytes, Cardiac - drug effects ; Myocytes, Cardiac - metabolism ; Myocytes, Cardiac - pathology ; Roxadustat ; Signal Transduction</subject><ispartof>Circulation Journal, 2020/05/25, Vol.84(6), pp.1028-1033</ispartof><rights>2020 THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c706t-8add95bd9877a63ff4aae7d308af26c4137b1c2c3c1f449baee37910a9da42523</citedby><cites>FETCH-LOGICAL-c706t-8add95bd9877a63ff4aae7d308af26c4137b1c2c3c1f449baee37910a9da42523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32213720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deguchi, Hiroko</creatorcontrib><creatorcontrib>Ikeda, Masataka</creatorcontrib><creatorcontrib>Ide, Tomomi</creatorcontrib><creatorcontrib>Tadokoro, Tomonori</creatorcontrib><creatorcontrib>Ikeda, Soichiro</creatorcontrib><creatorcontrib>Okabe, Kosuke</creatorcontrib><creatorcontrib>Ishikita, Akihito</creatorcontrib><creatorcontrib>Saku, Keita</creatorcontrib><creatorcontrib>Matsushima, Shouji</creatorcontrib><creatorcontrib>Tsutsui, Hiroyuki</creatorcontrib><title>Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background:Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury.Methods and Results:RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.Conclusions:RXD pretreatment may be a novel strategy against I/R injury.</description><subject>Animals</subject><subject>Cell Respiration - drug effects</subject><subject>Cells, Cultured</subject><subject>Disease Models, Animal</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Glycine - analogs & derivatives</subject><subject>Glycine - pharmacology</subject><subject>Hypoxia-Inducible Factor 1, alpha Subunit - metabolism</subject><subject>Hypoxia-inducible factor-1α (Hif-1α)</subject><subject>Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors</subject><subject>Hypoxia-Inducible Factor-Proline Dioxygenases - metabolism</subject><subject>Ischemia/reperfusion injury</subject><subject>Isoquinolines - pharmacology</subject><subject>Male</subject><subject>Mice, Inbred C57BL</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardial Infarction - pathology</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Myocardial Reperfusion Injury - metabolism</subject><subject>Myocardial Reperfusion Injury - pathology</subject><subject>Myocardial Reperfusion Injury - prevention & control</subject><subject>Myocytes, Cardiac - drug effects</subject><subject>Myocytes, Cardiac - metabolism</subject><subject>Myocytes, Cardiac - pathology</subject><subject>Roxadustat</subject><subject>Signal Transduction</subject><issn>1346-9843</issn><issn>1347-4820</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtLw0AQhxdRbH3cPUmOXqL7ymOPUqy2WATR8zLZnejGNKm7CZj_3tRWvcwMzDc_ho-QC0avGU_EjXHeVNezZcxUzKhQB2TKhMximXN6-DOnscqlmJCTECpKuaKJOiYTwTkTGadTsnxuv8D2oYMuWoH_QFsP0TPa3mCIVkNrwFsHdbQI5h3XDsbdBn3ZB9c20aKpej9ErolWzuAZOSqhDni-76fkdX73MnuIH5_uF7Pbx9hkNO3iHKxVSWFVnmWQirKUAJhZQXMoeWrk-FjBDDfCsFJKVQCiyBSjoCxInnBxSq52uRvffvYYOr12wWBdQ4NtHzQXueSM0yQbUbpDjW9D8FjqjXdr8INmVG8N6h-DerbUTOmtwfHkcp_eF2u0fwe_ykZgvgOqUdob_gHgO2dq3CfmUqfb8p_8D7yD19iIb2DGhxU</recordid><startdate>20200525</startdate><enddate>20200525</enddate><creator>Deguchi, Hiroko</creator><creator>Ikeda, Masataka</creator><creator>Ide, Tomomi</creator><creator>Tadokoro, Tomonori</creator><creator>Ikeda, Soichiro</creator><creator>Okabe, Kosuke</creator><creator>Ishikita, Akihito</creator><creator>Saku, Keita</creator><creator>Matsushima, Shouji</creator><creator>Tsutsui, Hiroyuki</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200525</creationdate><title>Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice</title><author>Deguchi, Hiroko ; Ikeda, Masataka ; Ide, Tomomi ; Tadokoro, Tomonori ; Ikeda, Soichiro ; Okabe, Kosuke ; Ishikita, Akihito ; Saku, Keita ; Matsushima, Shouji ; Tsutsui, Hiroyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c706t-8add95bd9877a63ff4aae7d308af26c4137b1c2c3c1f449baee37910a9da42523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Cell Respiration - drug effects</topic><topic>Cells, Cultured</topic><topic>Disease Models, Animal</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Glycine - analogs & derivatives</topic><topic>Glycine - pharmacology</topic><topic>Hypoxia-Inducible Factor 1, alpha Subunit - metabolism</topic><topic>Hypoxia-inducible factor-1α (Hif-1α)</topic><topic>Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors</topic><topic>Hypoxia-Inducible Factor-Proline Dioxygenases - metabolism</topic><topic>Ischemia/reperfusion injury</topic><topic>Isoquinolines - pharmacology</topic><topic>Male</topic><topic>Mice, Inbred C57BL</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardial Infarction - pathology</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Myocardial Reperfusion Injury - metabolism</topic><topic>Myocardial Reperfusion Injury - pathology</topic><topic>Myocardial Reperfusion Injury - prevention & control</topic><topic>Myocytes, Cardiac - drug effects</topic><topic>Myocytes, Cardiac - metabolism</topic><topic>Myocytes, Cardiac - pathology</topic><topic>Roxadustat</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deguchi, Hiroko</creatorcontrib><creatorcontrib>Ikeda, Masataka</creatorcontrib><creatorcontrib>Ide, Tomomi</creatorcontrib><creatorcontrib>Tadokoro, Tomonori</creatorcontrib><creatorcontrib>Ikeda, Soichiro</creatorcontrib><creatorcontrib>Okabe, Kosuke</creatorcontrib><creatorcontrib>Ishikita, Akihito</creatorcontrib><creatorcontrib>Saku, Keita</creatorcontrib><creatorcontrib>Matsushima, Shouji</creatorcontrib><creatorcontrib>Tsutsui, Hiroyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deguchi, Hiroko</au><au>Ikeda, Masataka</au><au>Ide, Tomomi</au><au>Tadokoro, Tomonori</au><au>Ikeda, Soichiro</au><au>Okabe, Kosuke</au><au>Ishikita, Akihito</au><au>Saku, Keita</au><au>Matsushima, Shouji</au><au>Tsutsui, Hiroyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2020-05-25</date><risdate>2020</risdate><volume>84</volume><issue>6</issue><spage>1028</spage><epage>1033</epage><pages>1028-1033</pages><issn>1346-9843</issn><issn>1347-4820</issn><eissn>1347-4820</eissn><abstract>Background:Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury.Methods and Results:RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.Conclusions:RXD pretreatment may be a novel strategy against I/R injury.</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>32213720</pmid><doi>10.1253/circj.CJ-19-1039</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-9843 |
| ispartof | Circulation Journal, 2020/05/25, Vol.84(6), pp.1028-1033 |
| issn | 1346-9843 1347-4820 1347-4820 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2384212057 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Cell Respiration - drug effects Cells, Cultured Disease Models, Animal Enzyme Inhibitors - pharmacology Glycine - analogs & derivatives Glycine - pharmacology Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Hypoxia-inducible factor-1α (Hif-1α) Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors Hypoxia-Inducible Factor-Proline Dioxygenases - metabolism Ischemia/reperfusion injury Isoquinolines - pharmacology Male Mice, Inbred C57BL Myocardial Infarction - metabolism Myocardial Infarction - pathology Myocardial Infarction - prevention & control Myocardial Reperfusion Injury - metabolism Myocardial Reperfusion Injury - pathology Myocardial Reperfusion Injury - prevention & control Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Myocytes, Cardiac - pathology Roxadustat Signal Transduction |
| title | Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Roxadustat%20Markedly%20Reduces%20Myocardial%20Ischemia%20Reperfusion%20Injury%20in%20Mice&rft.jtitle=Circulation%20Journal&rft.au=Deguchi,%20Hiroko&rft.date=2020-05-25&rft.volume=84&rft.issue=6&rft.spage=1028&rft.epage=1033&rft.pages=1028-1033&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.CJ-19-1039&rft_dat=%3Cproquest_cross%3E2384212057%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2384212057&rft_id=info:pmid/32213720&rfr_iscdi=true |